Article
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2008
Etienne-Grimaldi Marie-Christine, Formento Jean-Louis, Francoual Mireille, François Eric, Formento Patricia, Renée Nicole, Laurent-Puig Pierre, Chazal Maurice, Benchimol Daniel, Delpero Jean-Robert, Letoublon Christian, Pezet Denis, Seitz Jean-François, Milano Gérard
Abstract excerpt
PURPOSE: K-Ras mutations predict resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies. Because combinations of anti-EGFR with 5-fluorouracil (5-FU)-based chemotherapy are promising treatments, we analyzed the effect of K-Ras mutations in patients having received exclusive 5-FU therapy. EXPERIMENTAL DESIGN: This study was conducted on 93 stage IV colorectal cancer patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
